Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoPep Vaccine in Newly Diagnosed Glioma
NCT05557240Phase 1Unknown
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Sep 2022
- Primary completion
- Feb 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NeoPep S in glioblastoma (GBM), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Safety and tolerability at 40 weeks. Status: unknown.
02
Drugs
NeoPep S
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05557240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557240.